ProQR Therapeutics’ (PRQR) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research report released on Thursday morning,Benzinga reports. Chardan Capital currently has a $4.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the stock. HC Wainwright raised their target price on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $6.00 to $14.00 in a research report on Tuesday, October 29th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $7.60.

ProQR Therapeutics Stock Performance

Shares of ProQR Therapeutics stock opened at $3.29 on Thursday. The business has a 50 day moving average of $3.39 and a 200 day moving average of $2.38. ProQR Therapeutics has a 52 week low of $1.61 and a 52 week high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after purchasing an additional 51,663 shares in the last quarter. BNP Paribas Financial Markets raised its stake in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares during the last quarter. Finally, OneDigital Investment Advisors LLC raised its stake in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the last quarter. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).